HEPBEST 30'S

About

Hepbest 30's likely refers to Tenofovir Alafenamide (TAF), a novel prodrug of tenofovir. TAF is a highly potent nucleotide reverse transcriptase inhibitor (NRTI) that is more efficiently delivered to hepatocytes (liver cells) compared to Tenofovir Disoproxil Fumarate (TDF). This allows for a lower dose, resulting in significantly reduced systemic exposure to tenofovir, which translates to improved renal and bone safety profiles.

TAF works by inhibiting the activity of the Hepatitis B virus (HBV) polymerase, thereby preventing the replication of the viral genetic material. It is primarily indicated for the treatment of chronic Hepatitis B virus infection in adults and adolescents. Its targeted delivery to the liver makes it a highly effective option for suppressing HBV replication while minimizing potential adverse effects on the kidneys and bones, which were concerns with older tenofovir formulations.

Uses

• Treatment of chronic Hepatitis B virus (HBV) infection in adults.
• Management of chronic HBV in adolescents (aged 12 years and older).
• Used in patients with compensated liver disease.
• Effective in suppressing HBV viral replication.

Directions For Use

Take orally once daily with food, as directed by your healthcare provider. Swallow the tablet whole.

Benefits

• Highly effective in suppressing HBV viral load.
• Improved renal safety profile compared to TDF.
• Improved bone safety profile compared to TDF.
• Convenient once-daily dosing.
• Well-tolerated with a favorable safety profile.
• Targeted delivery to the liver for enhanced efficacy.

Side Effects

• Headache
• Nausea
• Abdominal pain
• Diarrhea
• Fatigue
• Flatulence
• Dyspepsia
• Elevated liver enzymes
• Rash
• Dizziness
• Vomiting
• Lactic acidosis (rare but serious)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption, as it can worsen liver disease, which is particularly relevant for patients with HBV.
• Pregnancy - Use in pregnancy only if the potential benefit justifies the potential risk to the fetus. Discuss risks and benefits with a healthcare provider.
• Breastfeeding - It is unknown if TAF is excreted in human milk. A decision should be made whether to discontinue breastfeeding or the drug, considering the importance of the drug to the mother.
• Liver - Monitor liver function regularly. Exacerbations of HBV can occur upon discontinuation of treatment. Use with caution in decompensated liver disease.
• Kidney - Use with caution in patients with severe renal impairment. Renal function should be monitored before and during treatment, though TAF has an improved renal safety profile compared to TDF.
• Lung - No specific lung-related contraindications. However, monitor for any unusual respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.